Intellia and Regeneron $125M CRISPR/Cas Partnerships
Intellia Therapeutics, Inc. (Cambridge, MA, USA) – one of the leaders in CRISPR/Cas9 gene editing tech is entering into a partnership with Regeneron Pharmaceuticals (New York, United States)- one of the leading drug developing companies, a partnership that will pay an upfront amount of 125 million dollars and equity stake to Intellia.
This agreement between them aims at advance CRISPR/Cas gene editing technology for in vivo therapeutic development. Additionally, this licensing and collaboration will also focus on the discovery, development and commercialization of new therapies and the technology development of the CRISPR/Cas platform.
The terms of six year bond include, Regeneron has the exclusive right to discover and develop CRISPR-based products against up to 10 targets, focused primarily on therapies for a broad range of diseases that may be treated by editing genes in the liver. Of the 10 targets, Regeneron can select up to five non-liver targets from Intellia’s ongoing and planned research. Along with this deal, Intellia has also announced filing of a matching initial public offering (IPO).
For Regeneron this joint venture is an opportunity to leverage the process of achieving Regeneron Genetics Center objectives, which has been collecting the genome for new genetic targets in drug development.
“Our industry-leading human genetics research with the Regeneron Genetics Center is already identifying important genetic targets, building on our long-standing expertise in genetic engineering,” said George Yancopoulos, the CSO at Regeneron. “We believe combining these capabilities with Intellia’s technology holds real promise for serious diseases that have been historically difficult to address, and expands our ability to help patients where antibody-based therapies may not be the optimal solution.”
Featured image credit: Chess Kings – Business Concept of Merger / Competition / Confrontation © EdSamuel (Stock Photo ID: 46671097)